TIME for a successful cancer vaccine in NSCLC?

Investigators of two phase 3 trials1,2 of nivolumab, a monoclonal antibody against PD-1, for second-line treatment of advanced non-small-cell lung cancer have reported significant improvements in overall survival and the proportion of patients achieving a response compared with standard cytotoxic chemotherapy. In the randomised phase 2b portion of the TIME trial, addition of TG4010 to standard first-line chemotherapy in advanced non-small-cell lung cancer resulted in significant improvement in the primary endpoint of progression-free survival and in an increased proportion of patients achieving a response.